Genital Yeast Infection Incidence: Jardiance vs Farxiga
Both Jardiance (empagliflozin) and Farxiga (dapagliflozin) carry similar risks of genital yeast infections, with no clinically meaningful difference between the two medications. The FDA drug label data and clinical trials show comparable rates of genital mycotic infections for both SGLT2 inhibitors.
Evidence from FDA Drug Labels and Clinical Trials
According to the Jardiance FDA label, genital mycotic infections occurred in 4.1% of patients on empagliflozin 10 mg and 3.7% on empagliflozin 25 mg, compared to 0.9% on placebo 1. These infections were more frequent in female patients and rarely led to discontinuation (0.2% of patients) 1.
A systematic review and meta-analysis found that all SGLT2 inhibitors significantly increase the risk of genital infections compared to placebo (RR 3.37,95% CI 2.89-3.93) and active comparators (RR 3.89,95% CI 3.14-4.82) 2. Importantly, this analysis showed no significant difference in genital infection rates between individual SGLT2 inhibitors.
Direct Comparative Evidence
A real-world comparative study directly assessed empagliflozin versus dapagliflozin and found lower rates of genital infections with empagliflozin (3.1%) compared to dapagliflozin (8.66%), with statistical significance (p=0.005) 3. However, this was a single study with methodological limitations, and the difference may reflect patient selection rather than true drug differences.
Another real-world analysis of female patients found that 25.1% of women on SGLT2 inhibitors experienced genital infections over 2.3 years, with risk factors including younger age, history of prior genital infections, and estrogen therapy 4. This study did not show meaningful differences between empagliflozin and dapagliflozin.
Clinical Implications and Risk Factors
The absolute difference in genital infection rates between these two drugs is minimal and should not drive medication selection. Both medications require the same precautions:
- Female patients have substantially higher risk than male patients for genital mycotic infections 1
- Most infections are mild-to-moderate and respond to standard antifungal therapy 1
- Risk factors include: younger age, history of prior genital infections, estrogen therapy, and poor glycemic control 4
- Discontinuation due to genital infections is rare (0.2% for both drugs) 1
Practical Management Approach
When choosing between Jardiance and Farxiga, base your decision on cardiovascular and renal outcomes data, cost, and formulary considerations—not on genital infection risk, as this is essentially equivalent between the two drugs 5, 6, 7.
For patients at high risk for genital infections:
- Counsel about proper hygiene and early recognition of symptoms
- Consider prophylactic antifungal therapy in patients with recurrent infections
- Maintain awareness that infections typically respond to standard topical azole therapy 8, 9
Common pitfall: Avoiding SGLT2 inhibitors entirely in women due to infection concerns. The cardiovascular and renal benefits of these medications far outweigh the manageable risk of treatable genital infections in most patients 5, 10, 11.